Zavzpret FDA Approval History
Last updated by Judith Stewart, BPharm on March 14, 2023.
FDA Approved: Yes (First approved March 9, 2023)
Brand name: Zavzpret
Generic name: zavegepant
Dosage form: Nasal Spray
Company: Pfizer Inc.
Treatment for: Migraine
Zavzpret (zavegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine.
- Migraine is a severe pulsating headache of moderate to severe pain intensity, often associated with nausea or vomiting, phonophobia, and photophobia. Attacks can last from four to 72 hours.
- Zavzpret belongs to the class of drugs called CGRP receptor antagonists. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide which is thought to play a causal role in migraine.
- Zavzpret is a nasal spray administered as a single spray in one nostril, as needed. The maximum dose that may be given in a 24-hour period is 10 mg (one spray). Clinical studies have shown that Zavzpret demonstrated relief from migraine pain in 15 minutes, with relief lasting up to 48 hours for many patients.
- Zavzpret may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onset.
- Warnings and precautions associated with Zavzpret include hypersensitivity reactions.
- Common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.
Development timeline for Zavzpret
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
